Toronto-based Cybin Inc. (NYSE:CYBN) will be raising roughly $150 million through the private placement of more than 348 million common...
Toronto-based Cybin Inc. (NYSE:CYBN) will be raising roughly $150 million through the private placement of more than 348 million common shares to continue...
The new Nasdaq-listed entity trades under the ticker symbol PBM. The post Australia approves Psyence phase 2b study as it finalizes merger appeared first...
The JAMA (Journal of American Medical Association) Psychiatry published an article calling for more research and surveillance of ketamine treatments. Citing...
The company is still reeling with negative cash flows and net losses. The post Mynd Life Sciences cuts losses, but faces going concern doubts appeared...
The company said its operations are funded through 2025. The post GH Research pushes forward with DMT trials, drug approvals appeared first on Green Market...
The firm has a negative working capital of nearly $1 million. The post Psyence reports no revenue in Q4, but returns a profit appeared first on...
The psychoactive compound, MEAI, is dubbed a "binge mitigating agent." The post Clearmind trials new alcohol disorder fix appeared first on Green Market...
Enveric Biosciences (NASDAQ: ENVB) is selling one of its cancer-related patent portfolios for an undisclosed amount. Enveric said it plans to continue...
New potential therapies like MDMA will need more infrastructure beyond just buildings. The post Prepping the psychedelic industry for MDMA approval appeared...